Straits Times Index
3,325.58 -0.70 (-0.02%) Nikkei
39,750.50 +577.35 (+1.47%) Hang Seng
18,069.75 -3.15 (-0.02%) FTSE 100
8,247.79 -33.76 (-0.41%) Bitcoin USD
61,787.56 +598.28 (+0.98%) CMC Crypto 200
1,284.29 +35.16 (+2.81%)
QGEN Nov 2024 55.000 call
| Previous close | 0.7400 |
| Open | 0.9100 |
| Bid | 0.4500 |
| Ask | 0.8000 |
| Strike | 55.00 |
| Expiry date | 2024-11-15 |
| Day's range | 0.7400 - 0.9100 |
| Contract range | N/A |
| Volume | |
| Open interest | 368 |
ZacksQIAGEN's (QGEN) New QCI Interpret Release Enhances AI Functions
QIAGEN's (QGEN) latest QCI Interpret release improves the performance of high-throughput NGS labs.
ReutersQiagen eyes sales growth of 7% per year until 2028
Diagnostics company Qiagen said on Monday it was targeting 7% currency-adjusted sales growth per year until 2028 on lab testing machines for infections and cancer, as it maps out its post-pandemic strategy. Qiagen has said it will return to growth in adjusted earnings this year, recovering from last year's drop in profit when demand for coronavirus lab tests plunged. "Between life sciences and clinical application, our market is growing between 4% and 6%, so saying 7% means outpacing the market and therefore taking market share," CEO Thierry Bernard told Reuters.
ZacksQIAGEN (QGEN) Debuts dPCR Microbial DNA Detection Assays
QIAGEN (QGEN) launches new QIAcuity dPCR assays for microbial applications, enhancing infectious disease research and surveillance.
